RxDoctor Payments Data

Stuart Chalew

Pediatric Endocrinology · New Orleans, LANPI 1558384594

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $4,340 of the $6,908 with a category attached, or 62.8%. Medtronic accounts for 66.0% of it on its own, with 24 other manufacturers making up the rest. Reporting peaked in 2021 at $3,390 and has fallen 90.0% since, to $340 in 2025.

$6,908in general payments, 2019–2025

Across 103 payments — averaging $67.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$5K
  • Novo Nordisk$474
  • Ascendis Pharma Endocrinology Inc$264
  • AbbVie$164
  • Mannkind Corporation$164
  • Dexcom, Inc.$155
  • plus $1K from 19 others
$37,914in research payments, 2019–2025

Across 15 payments — averaging $2527.58 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Medtronic$27K
  • Eli Lilly$11K
  • Merck$92

What the payments were for

  • Speaking & faculty fees$4,34063%
  • Food & beverage$2,49936%
  • Education$691%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few pediatric endocrinology providers in Louisianato place this figure against a meaningful peer group, so we don't.

Other pediatric endocrinology in New Orleans

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →